3 years on, FDA still evaluating Qdenga dengue vaccine application

MANILA, Philippines — The proposed new generation anti-dengue vaccine remains under review by the Food and Drug Administration (FDA) three years after it applied for registration, according to Malacañang. Citing a statement from the Department of Health (DOH), Palace press officer Claire Castro said the application of Japanese pharmaceutical company Takeda for the certificate of product

By mareyes